| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways S Zhang, WC Huang, P Li, H Guo, SB Poh, SW Brady, Y Xiong, LM Tseng, ... Nature medicine 17 (4), 461-469, 2011 | 606 | 2011 |
| PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer FJ Esteva, H Guo, S Zhang, C Santa-Maria, S Stone, JS Lanchbury, ... The American journal of pathology 177 (4), 1647-1656, 2010 | 367 | 2010 |
| 14-3-3ζ cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition J Lu, H Guo, W Treekitkarnmongkol, P Li, J Zhang, B Shi, C Ling, X Zhou, ... Cancer cell 16 (3), 195-207, 2009 | 227 | 2009 |
| 14-3-3ζ overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival CL Neal, J Yao, W Yang, X Zhou, NT Nguyen, J Lu, CG Danes, H Guo, ... Cancer research 69 (8), 3425-3432, 2009 | 225 | 2009 |
| SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases S Zhang, WC Huang, L Zhang, C Zhang, FJ Lowery, Z Ding, H Guo, ... Cancer research 73 (18), 5764-5774, 2013 | 121 | 2013 |
| Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance J Lu, M Tan, WC Huang, P Li, H Guo, LM Tseng, X Su, WT Yang, ... Clinical Cancer Research 15 (4), 1326-1334, 2009 | 112 | 2009 |
| Clinicopathological, immunohistochemical, and ultrastructural study of 13 cases of melanotic schwannoma. H Zhang, G Yang, H Chen, B Wei, Q Ke, H Guo, L Ye, H Bu, K Yang, ... Chinese medical journal 118 (17), 1451-1461, 2005 | 106 | 2005 |
| Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy J He, HJ Lee, S Saha, D Ruan, H Guo, CH Chan Cell death & disease 10 (4), 1-16, 2019 | 66 | 2019 |
| Sphingosine kinase 1 signaling promotes metastasis of triple-negative breast cancer S Acharya, J Yao, P Li, C Zhang, FJ Lowery, Q Zhang, H Guo, J Qu, ... Cancer research 79 (16), 4211-4226, 2019 | 58 | 2019 |
| Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with … H Guo, Q Ding, Y Gong, MZ Gilcrease, M Zhao, J Zhao, D Sui, Y Wu, ... Breast Cancer Research 22 (1), 1-18, 2020 | 53 | 2020 |
| Upregulation of neutrophil gelatinase–associated lipocalin by ErbB2 through nuclear factor-κB activation SH Li, VS Hawthorne, CL Neal, S Sanghera, J Xu, J Yang, H Guo, ... Cancer research 69 (24), 9163-9168, 2009 | 43 | 2009 |
| Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the US population Z Zhou, CJ Kinslow, H Hibshoosh, H Guo, SK Cheng, C He, MS Gentry, ... Journal of clinical medicine 8 (2), 246, 2019 | 37 | 2019 |
| 14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation SK Rehman, SH Li, SL Wyszomierski, Q Wang, P Li, O Sahin, Y Xiao, ... Cancer research 74 (1), 363-373, 2014 | 34 | 2014 |
| Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma X Huang, Q Ding, H Guo, Y Gong, J Zhao, M Zhao, D Sui, Y Wu, H Chen, ... Human Pathology 108, 42-50, 2021 | 26 | 2021 |
| SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis B Dong, Y Gao, X Kang, H Gao, J Zhang, H Guo, MJ You, W Xue, J Cheng, ... Oncotarget 7 (49), 80435, 2016 | 26 | 2016 |
| Effects of RNAi-mediated Smad4 silencing on growth and apoptosis of human rhabdomyosarcoma cells L Ye, H Zhang, L Zhang, G Yang, Q Ke, H Guo, H Bu International journal of oncology 29 (5), 1149-1157, 2006 | 25 | 2006 |
| Immunohistochemical profile and fluorescence in situ hybridization analysis of diffuse large B-cell lymphoma in northern China T Li, LJ Medeiros, P Lin, H Yin, M Littlejohn, W Im, PA Lennon, P Hu, ... Archives of pathology & laboratory medicine 134 (5), 759-765, 2010 | 20 | 2010 |
| Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, HER2 negative breast cancer DK Marks, RD Gartrell, M El Asmar, S Boboila, T Hart, Y Lu, Q Pan, J Yu, ... Frontiers in oncology 10, 968, 2020 | 19 | 2020 |
| Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma GUO Hua, H Zhang, S Wang, YE Lü, G Yang, BU Hong Chinese medical journal 120 (6), 515-521, 2007 | 17 | 2007 |
| Reassessment of the pathological diagnosis in 33 cases of malignant fibrous histiocytoma H Guo, Y Xiong, L Nong, S Zhang, T Li Beijing da xue xue bao. Yi xue ban= Journal of Peking University. Health …, 2008 | 12 | 2008 |
